EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CDKN1B (p27/kip1) enhances drug-tolerant persister CTCs by restricting polyploidy following mitotic inhibitors

Elad Horwitz, Taronish D Dubash, Annamaria Szabolcs, Ben S Wittner, Johannes Kreuzer iD, Robert Morris, Aditya Bardia, Brian Chirn, Devon Wiley, Dante Che, Hunter C Russell, Xcanda Ixchel Herrera Lopez und 8 weitere

Proceedings of the National Academy of Sciences · 2025

DOI: 10.1073/pnas.2507203122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Elad Horwitz und 19 weiteren Autor:innen. Beteiligte Einrichtung: Krantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129. Hauptthemen laut MEDLINE: Breast Neoplasms, Polyploidy, Cyclin-Dependent Kinase Inhibitor p27, Neoplastic Cells, Circulating. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Howard Hughes Medical Institute (HHMI), NCI NIH HHS, National Foundation for Cancer Research (NFCR).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mitotic inhibitor docetaxel (DTX) is often used to treat endocrine-refractory metastatic breast cancer, but initial responses are mitigated as patients develop disease progression. Using a cohort of ex vivo cultured circulating tumor cells (CTCs) from patients with heavily pretreated breast cancer (n=18), we find distinct patterns of response to DTX, which are intrinsic and independent of past clinical treatment with taxanes. In some CTC cultures, treatment with a single dose of DTX results in complete cell killing, associated with accumulation of nonviable polyploid (≥8 N) cells arising from endomitosis. In other CTC cultures, a transient viable drug-tolerant persister (DTP) population emerges, ultimately enabling renewed proliferation of CTCs with preserved parental cell ploidy and restored DTX sensitivity identical to that of the pretreated culture. In these CTCs, efficient cell cycle exit generates a ≤4 N drug-tolerant state dependent on CDKN1B (p27/kip1). Exposure to DTX triggers stabilization of CDKN1B through AKT-mediated phosphorylation at serine 10. Suppression of CDKN1B reduces the number of persister CTCs, increases ≥8 N mitotic cells and abrogates regrowth after DTX exposure. Thus, CDKN1B-mediated suppression of endomitosis contributes to the initiation of a reversible drug-tolerant persister state following mitotic inhibitors in advanced patient-derived breast cancer cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsPolyploidyCyclin-Dependent Kinase Inhibitor p27Neoplastic Cells, CirculatingMitosisHumansFemaleDocetaxelDrug Resistance, NeoplasmCell Line, TumorTaxoidsAntineoplastic Agents

Stichwörter der Autor:innen

CDKN1Bbreast cancercirculating tumor cellsdrug-tolerant persister cellstaxanes

Substanzen

Cyclin-Dependent Kinase Inhibitor p27DocetaxelCDKN1B protein, humanTaxoidsAntineoplastic Agents

Autor:innen und Institutionen

  • Krantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129.
  • Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114.
  • Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • HHMI, Chevy Chase, MD 20815.

ORCID-Profile: Johannes Kreuzer, Ezgi Antmen, David T Ting, Daniel A Haber

Förderung

  • Howard Hughes Medical Institute (HHMI)
  • NCI NIH HHS
  • National Foundation for Cancer Research (NFCR)
  • Breast Cancer Research Foundation (BCRF)
  • HHS | National Institutes of Health (NIH)

Zitieren

APA

Horwitz, E., Dubash, T. D., Szabolcs, A., Wittner, B. S., Kreuzer, J., Morris, R., Bardia, A., Chirn, B., Wiley, D., Che, D., Russell, H. C., Herrera Lopez, X. I., Fox, D. B., Antmen, E., Burr, R., Ting, D. T., Haas, W., Sade-Feldman, M., Maheswaran, S., & Haber, D. A. (2025). CDKN1B (p27/kip1) enhances drug-tolerant persister CTCs by restricting polyploidy following mitotic inhibitors. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2507203122

Vancouver

Horwitz E, Dubash TD, Szabolcs A, Wittner BS, Kreuzer J, Morris R, et al. CDKN1B (p27/kip1) enhances drug-tolerant persister CTCs by restricting polyploidy following mitotic inhibitors. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2507203122

BibTeX
@article{Horwitz2025,
  author = {Horwitz, Elad and Dubash, Taronish D and Szabolcs, Annamaria and Wittner, Ben S and Kreuzer, Johannes and Morris, Robert and Bardia, Aditya and Chirn, Brian and Wiley, Devon and Che, Dante and Russell, Hunter C and Herrera Lopez, Xcanda Ixchel and Fox, Douglas B and Antmen, Ezgi and Burr, Risa and Ting, David T and Haas, Wilhelm and Sade-Feldman, Moshe and Maheswaran, Shyamala and Haber, Daniel A},
  title = {CDKN1B (p27/kip1) enhances drug-tolerant persister CTCs by restricting polyploidy following mitotic inhibitors},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  doi = {10.1073/pnas.2507203122}
}
Kostenlos starten →